{"id":46588,"date":"2022-07-26T19:01:40","date_gmt":"2022-07-26T17:01:40","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/first-german-evba-procedure-is-performed-with-new-heart-failure-therapy-approach\/"},"modified":"2022-07-26T19:01:40","modified_gmt":"2022-07-26T17:01:40","slug":"first-german-evba-procedure-is-performed-with-new-heart-failure-therapy-approach","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/first-german-evba-procedure-is-performed-with-new-heart-failure-therapy-approach\/","title":{"rendered":"First German EVBA Procedure is Performed with New Heart Failure Therapy Approach"},"content":{"rendered":"
\n

\nLatest Data and Live Broadcast Show Promise of Vascular Dynamics\u2019 MobiusHD Device<\/i>\n<\/p>\n

IRVINE, Calif.–(BUSINESS WIRE)–Vascular Dynamics, Inc. (VDI)<\/a>, a privately held medical device company focused on developing game-changing endovascular device-based solutions for patients suffering from heart failure, announced that the endovascular baroreflex amplification (EVBA) procedure using its MobiusHD device to treat patients with heart failure was featured during last month\u2019s CSI Frankfurt 2022 25th<\/sup> anniversary Congress.\n<\/p>\n

\nThe first German EVBA procedure treating heart failure was performed by Horst Sievert, MD, Director of the CardioVascular Center in Frankfurt, and was broadcast live during the meeting. Dr. Sievert stated that the placement in this case, while using established, relatively straightforward techniques, was \u201cperfect.\u201d This case also represented the 30th<\/sup> patient enrolled in the ongoing clinical trial titled, \u201cA Feasibility Study Exploring the Effect of the MobiusHD Device in Patients with Heart Failure.\u201d\n<\/p>\n

\nThe EVBA approach allows for precise placement of the MobiusHD implant in the pre-procedurally targeted location where baroreceptors are located along the carotid body. The technique can be completed in less than 30 minutes and offers a potential solution for symptomatic heart failure patients who are not responding to drug treatment.\n<\/p>\n

\nCSI Education has selected the live case to be recognized as its \u201cPodcase of the Month,\u201d and it can be viewed here<\/a>.\n<\/p>\n

\nAlso during the CSI Frankfurt meeting, Kerstin Piayda, MD of the CardioVascular Center in Frankfurt, presented updated results<\/a> from the clinical trial. Improvements in outcomes for patients receiving EVBA treatment with the MobiusHD device including 3-, 6-, and 12-month follow-up were reported. Based on the results of quality of life, six-minute walk distance (6MWD), and NT-proBNP biomarker measurements, almost all of the study patients had positive responses at 12 months (90% with improved quality of life and 100% showed improvements in 6MWD and NT-proBNP levels), and a high percentage benefited from what were considered to be clinically meaningful results. Dr. Piayda also shared data reflecting the promising trend of reduced heart failure hospitalization for these patients after treatment at 6 and 12 months.\n<\/p>\n

\n\u201cResults to date from the feasibility study in heart failure patients have been very promising,\u201d commented Ed Roschak, CEO of Vascular Dynamics. \u201cWith our recently announced $20 million financing round, we are currently expanding these efforts to multiple clinical centers around the world and are continuing to enroll more patients.\u201d\n<\/p>\n

\n“MobiusHD\u201d is a registered trademark of Vascular Dynamics, Inc.<\/i>\n<\/p>\n

\nAbout Vascular Dynamics, Inc.<\/b>\n<\/p>\n

\nVascular Dynamics develops innovative, endovascular platform technologies to offer compelling treatment options for patients at risk of life-threatening conditions underserved by conventional treatments. The company\u2019s MobiusHD technology features the first endovascular device to use the body\u2019s natural baroreflex mechanism to modulate the autonomic nervous system and help restore sympathetic balance. Clinical evaluations are in progress. More information is available at <\/i>www.vasculardynamics.com<\/i><\/a>.<\/i>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nPaul Williams
\n
310-569-0023
\n
paul@medialinecommunications.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Latest Data and Live Broadcast Show Promise of Vascular Dynamics\u2019 MobiusHD Device IRVINE, Calif.–(BUSINESS WIRE)–Vascular Dynamics, Inc. (VDI), a privately held medical device company focused on developing game-changing endovascular device-based solutions for patients suffering from heart failure, announced that the endovascular baroreflex amplification (EVBA) procedure using its MobiusHD device to treat patients with heart failure … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46588","6":"format-standard","7":"category-industry"},"yoast_head":"\nFirst German EVBA Procedure is Performed with New Heart Failure Therapy Approach - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/first-german-evba-procedure-is-performed-with-new-heart-failure-therapy-approach\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"First German EVBA Procedure is Performed with New Heart Failure Therapy Approach - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Latest Data and Live Broadcast Show Promise of Vascular Dynamics\u2019 MobiusHD Device IRVINE, Calif.–(BUSINESS WIRE)–Vascular Dynamics, Inc. (VDI), a privately held medical device company focused on developing game-changing endovascular device-based solutions for patients suffering from heart failure, announced that the endovascular baroreflex amplification (EVBA) procedure using its MobiusHD device to treat patients with heart failure ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/first-german-evba-procedure-is-performed-with-new-heart-failure-therapy-approach\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-26T17:01:40+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/first-german-evba-procedure-is-performed-with-new-heart-failure-therapy-approach\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/first-german-evba-procedure-is-performed-with-new-heart-failure-therapy-approach\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"First German EVBA Procedure is Performed with New Heart Failure Therapy Approach\",\"datePublished\":\"2022-07-26T17:01:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/first-german-evba-procedure-is-performed-with-new-heart-failure-therapy-approach\\\/\"},\"wordCount\":480,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/first-german-evba-procedure-is-performed-with-new-heart-failure-therapy-approach\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/first-german-evba-procedure-is-performed-with-new-heart-failure-therapy-approach\\\/\",\"name\":\"First German EVBA Procedure is Performed with New Heart Failure Therapy Approach - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2022-07-26T17:01:40+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/first-german-evba-procedure-is-performed-with-new-heart-failure-therapy-approach\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/first-german-evba-procedure-is-performed-with-new-heart-failure-therapy-approach\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/first-german-evba-procedure-is-performed-with-new-heart-failure-therapy-approach\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"First German EVBA Procedure is Performed with New Heart Failure Therapy Approach\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"First German EVBA Procedure is Performed with New Heart Failure Therapy Approach - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/first-german-evba-procedure-is-performed-with-new-heart-failure-therapy-approach\/","og_locale":"en_US","og_type":"article","og_title":"First German EVBA Procedure is Performed with New Heart Failure Therapy Approach - Pharma Trend","og_description":"Latest Data and Live Broadcast Show Promise of Vascular Dynamics\u2019 MobiusHD Device IRVINE, Calif.–(BUSINESS WIRE)–Vascular Dynamics, Inc. (VDI), a privately held medical device company focused on developing game-changing endovascular device-based solutions for patients suffering from heart failure, announced that the endovascular baroreflex amplification (EVBA) procedure using its MobiusHD device to treat patients with heart failure ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/first-german-evba-procedure-is-performed-with-new-heart-failure-therapy-approach\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-26T17:01:40+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/first-german-evba-procedure-is-performed-with-new-heart-failure-therapy-approach\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/first-german-evba-procedure-is-performed-with-new-heart-failure-therapy-approach\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"First German EVBA Procedure is Performed with New Heart Failure Therapy Approach","datePublished":"2022-07-26T17:01:40+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/first-german-evba-procedure-is-performed-with-new-heart-failure-therapy-approach\/"},"wordCount":480,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/first-german-evba-procedure-is-performed-with-new-heart-failure-therapy-approach\/","url":"https:\/\/pharma-trend.com\/en\/first-german-evba-procedure-is-performed-with-new-heart-failure-therapy-approach\/","name":"First German EVBA Procedure is Performed with New Heart Failure Therapy Approach - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2022-07-26T17:01:40+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/first-german-evba-procedure-is-performed-with-new-heart-failure-therapy-approach\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/first-german-evba-procedure-is-performed-with-new-heart-failure-therapy-approach\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/first-german-evba-procedure-is-performed-with-new-heart-failure-therapy-approach\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"First German EVBA Procedure is Performed with New Heart Failure Therapy Approach"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46588","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46588"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46588\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46588"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46588"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46588"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}